By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Abide Therapeutics 

3545 John Hopkins Court
Suite 250
San Diego  California  92121  U.S.A.
Phone: 858-427-2590 Fax: n/a


Abide Therapeutics' mission is to develop innovative medicines for the benefit of human health that target serine hydrolases, one of the largest enzyme classes in nature with validated, but mostly untapped therapeutic potential.

Key Statistics

Ownership: Private

Web Site: Abide Therapeutics
Employees: n/a


Company News
Abide Therapeutics Announces Dosing Of First Subject In fMRI Imaging Study To Investigate Brain Activity Patterns Associated With ABX-1431 5/10/2017 6:50:08 AM
Abide Therapeutics Announces Dosing Of First Patient In Phase Ib Study Of ABX-1431 In Tourette Syndrome And Collaboration With Tourette Association Of America 4/18/2017 6:46:06 AM
Abide Therapeutics Announces First Patient Dosed In Phase 1b Study To Assess The Effect Of ABX-1431 In Patients With Functional Dyspepsia 12/14/2016 6:41:38 AM
Abide Therapeutics Announces First Subject Dosed In PET Occupancy Study with [18F]ABX-1488, A Proprietary Human Monoacylglycerol Lipase (MGLL)-Specific PET Ligand 5/10/2016 6:23:37 AM
Abide Therapeutics Appoints Richard N. Kender To Board Of Directors 1/19/2016 6:45:20 AM
Abide Therapeutics Appoints Dr. Chan Beals As Chief Medical Officer 1/6/2016 9:29:58 AM
Abide Therapeutics Appoints Donald Hertzog As Vice President, Early Lead Identification 9/8/2015 7:24:26 AM
Abide Therapeutics Announces First Subject Dosed In First-In-Human Clinical Study Of ABX-1431, An Investigational Endocannabinoid System Modulator 7/7/2015 6:26:21 AM
Abide Therapeutics Announces A Collaborative Agreement With The University of Oxford 11/4/2014 8:58:23 AM
Abide Therapeutics Appoints Nancy Thornberry To Board Of Directors 7/29/2014 8:50:01 AM